Clinical trial
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac…
NCT00170794 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00170794 |
|---|---|
| Title | Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. |
| Official title | A One Year, Multicenter, Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiac Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus (RAD001) |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 18, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: